What development phase is ISOETHARINE in?

ISOETHARINE is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

ISOETHARINE

FDA-approved approved Small molecule Quality 0/100

Isoetharine is a marketed drug with a key composition patent expiring in 2028, positioning it as an established player in its therapeutic segment. The drug's primary strength lies in its current market presence, leveraging its well-established mechanism of action. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	ISOETHARINE
Modality	Small molecule
Phase	FDA-approved
First approval	1979

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ISOETHARINE CI brief — competitive landscape report
ISOETHARINE updates RSS · CI watch RSS